Advanced search
Publication Cover
Leukemia & Lymphoma Volume 47, 2006 - Issue 6
Submit an article Journal homepage
114
Views
20
CrossRef citations to date
0
Altmetric
Original

Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing

Edgar Faber Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine, Palacky University in Olomouc, Olomouc, Czech RepublicCorrespondence[email protected]
,
Jitka Naušová Institute of Biology, Faculty of Medicine, Palacky University in Olomouc, Olomouc, Czech Republic
,
Marie Jarošová Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine, Palacky University in Olomouc, Olomouc, Czech Republic
,
Merrill J. Egorin University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA
,
Milena Holzerová Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine, Palacky University in Olomouc, Olomouc, Czech Republic
,
Šárka Rožmanová Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine, Palacky University in Olomouc, Olomouc, Czech Republic
,
Ivana Marešová Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine, Palacky University in Olomouc, Olomouc, Czech Republic
,
Vladimír Divoký Institute of Biology, Faculty of Medicine, Palacky University in Olomouc, Olomouc, Czech Republic
&
Karel Indrák Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine, Palacky University in Olomouc, Olomouc, Czech Republic
 show all
Pages 1082-1090 | Received 18 Jul 2005, Accepted 20 Dec 2005, Published online: 01 Jul 2009

Citations (20)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Amir Imran Faisal Hamdi, Soon Hin How, Mohammad Kaisarul Islam, Jonathan Chee Woei Lim & Johnson Stanslas. (2022) Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?. Expert Review of Anticancer Therapy 22:12, pages 1309-1323.
Read now
Edgar Faber, Martina Divoká, Ivana Skoumalová, Martin Novák, Ivana Marešová, Kateřina Mičová, David Friedecký, Tomáš Adam, Marie Jarošová & Karel Indrák. (2016) A lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatment. Leukemia & Lymphoma 57:2, pages 370-375.
Read now
Maria Moschovi, Maria Adamaki, Anastasia Athanasiadou, Aspasia Divane, Anna Karytianou & Natalia Tourkantoni. (2015) Possible implication of IKAROS gene deletion and BCR–ABL1 variants in progression of chronic myeloid leukemia to lymphoid blast crisis in childhood: a single-institution experience. Leukemia & Lymphoma 56:8, pages 2460-2462.
Read now

Articles from other publishers (17)

Hyung-Don Kim, Changhoon Yoo, Min-Hee Ryu & Yoon-Koo Kang. (2023) A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours. British Journal of Cancer 129:2, pages 275-282.
Crossref
Fiorina Giona, Francesco Malaspina, Maria Caterina Putti, Saverio Ladogana, Rosamaria Mura, Roberta Burnelli, Nadia Vacca, Lorenzo Rizzo, Simona Bianchi, Maria Luisa Moleti, Anna Maria Testi, Andrea Biondi, Franco Locatelli, Giuseppe Saglio & Robin Foà. (2020) Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia. British Journal of Haematology 188:6.
Crossref
Faouzi Djebbari, Nicola Stoner & Verna Teresa Lavender. (2018) A systematic review of non-standard dosing of oral anticancer therapies. BMC Cancer 18:1.
Crossref
N Pizzolato, D Persano Adorno, D Valenti & B Spagnolo. (2016) Intermittent targeted therapies and stochastic evolution in patients affected by chronic myeloid leukemia. Journal of Statistical Mechanics: Theory and Experiment 2016:5, pages 054032.
Crossref
Ji Hoon Jung, Miyong Yun, Eun-Jeong Choo, Sun-Hee Kim, Myoung-Seok Jeong, Deok-Beom Jung, Hyemin Lee, Eun-Ok Kim, Nobuo Kato, Bonglee Kim, Sanjay K Srivastava, Kunihiro Kaihatsu & Sung-Hoon Kim. (2015) A derivative of epigallocatechin-3-gallate induces apoptosis via SHP-1-mediated suppression of BCR-ABL and STAT3 signalling in chronic myelogenous leukaemia. British Journal of Pharmacology 172:14, pages 3565-3578.
Crossref
Michael J. Mauro. (2013) Striving to achieve safe, permanent treatment discontinuation in chronic myeloid leukemia. Leukemia Research 37:11, pages 1395-1403.
Crossref
Edgar Faber, Adam Kuba, Jana Zapletalova, Martina Divoka, Peter Rohon, Milena Holzerova, Marie Jarosova & Karel Indrak. (2013) Interferon-alpha in chronic myeloid leukemia revisited: A long-term retrospective study in Central and Northern Moravia. Biomedical Papers 157:3, pages 248-256.
Crossref
Peter Rohon, Edgar Faber, Martina Divoka, Sarka Rozmanova, David Friedecky, Marie Jarosova & Karel Indrak. (2013) A significant proportion of patients with chronic myeloid leukemia and suboptimal response according to European Leukemia Net criteria have excellent prognosis without treatment change. Biomedical Papers 157:2, pages 181-188.
Crossref
Yuchen Fan, Wenwen Du, Bing He, Fengying Fu, Lan Yuan, Hounan Wu, Wenbing Dai, Hua Zhang, Xueqing Wang, Jiancheng Wang, Xuan Zhang & Qiang Zhang. (2013) The reduction of tumor interstitial fluid pressure by liposomal imatinib and its effect on combination therapy with liposomal doxorubicin. Biomaterials 34:9, pages 2277-2288.
Crossref
Edgar Faber, David Friedeck?Kate?ina Mi?ov???rka Ro?manov?Martina Divok?Marie Jaro?ov?Karel Indr?k & Tom?? Adam. (2012) Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting. Annals of Hematology 91:6, pages 923-929.
Crossref
Nicola Pizzolato, Dominique Persano Adorno, Davide Valenti & Bernardo Spagnolo. (2011) Stochastic dynamics of leukemic cells under an intermittent targeted therapy. Theory in Biosciences 130:3, pages 203-210.
Crossref
Peter Rohon, Martina Divoka, Lenka Calabkova, Renata Mojzikova, Beata Katrincsakova, Zuzana Rusinakova, Anna Lapcikova, Ludek Raida, Edgar Faber, Marie Jarosova, Vladimir Divoky & Karel Indrak. (2011) IDENTIFICATION OF E6A2 BCR-ABL FUSION IN A PHILADELPHIA-POSITIVE CML WITH MARKED BASOPHILIA: IMPLICATIONS FOR TREATMENT STRATEGY. Biomedical Papers 155:2, pages 187-190.
Crossref
Edgar Faber, Renata Mojzikova, Radek Plachy, Sarka Rozmanova, Marek Stastny, Martina Divoka, Marie Jarosova, Karel Indrak & Vladimir Divoky. (2010) Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation. Leukemia Research 34:4, pages e91-e93.
Crossref
Massimo Breccia, Laura Cannella, Caterina Stefanizzi, Michelina Santopietro, Rosa De Cuia, Daniela Diverio & Giuliana Alimena. (2009) Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease. Leukemia Research 33:5, pages 645-648.
Crossref
Edgar Faber. (2009) Has the time come for induction and maintenance imatinib therapy in chronic myeloid leukemia?. Leukemia Research 33:5, pages 605-606.
Crossref
. (2007) Current Awareness in Hematological Oncology. Hematological Oncology 25:1, pages 44-51.
Crossref
. (2006) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 16:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.